Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew J Tebben

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Journal of Molecular Biology|January 13, 2015
Developing Adnectins that target SRC co-activator binding to PXR: a structural approach toward understanding promiscuity of PXRJaved A Khan, Daniel M Camac, Simon Low, et al.
Journal of Medicinal Chemistry|April 4, 2007
Dihydropyridopyrazinones and dihydropteridinones as corticotropin-releasing factor-1 receptor antagonists: structure-activity relationships and computational modelingCarolyn D Dzierba, Andrew J Tebben, Richard G Wilde, et al.
ACS Medicinal Chemistry Letters|April 21, 2015
Discovery of a Potent and Orally Bioavailable Dual Antagonist of CC Chemokine Receptors 2 and 5Percy H Carter, Gregory D Brown, Robert J Cherney, et al.
Bioorganic & Medicinal Chemistry Letters|December 22, 2007
From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxisJoseph B Santella, Daniel S Gardner, Wenqing Yao, et al.
ACS Medicinal Chemistry Letters|January 29, 2016
Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate CancerAudris Huang, Lata Jayaraman, Aberra Fura, et al.
Journal of Medicinal Chemistry|October 4, 2012
Acyl guanidine inhibitors of β-secretase (BACE-1): optimization of a micromolar hit to a nanomolar lead via iterative solid- and solution-phase library synthesisSamuel W Gerritz, Weixu Zhai, Shuhao Shi, et al.
Bioorganic & Medicinal Chemistry Letters|May 28, 2013
The discovery of BMS-457, a potent and selective CCR1 antagonistDaniel S Gardner, Joseph B Santella, John V Duncia, et al.
ACS Medicinal Chemistry Letters|June 18, 2021
Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2Michael G Yang, Zili Xiao, Rulin Zhao, et al.
Bioorganic & Medicinal Chemistry Letters|November 17, 2010
Synthesis and SAR of indole-and 7-azaindole-1,3-dicarboxamide hydroxyethylamine inhibitors of BACE-1Lawrence R Marcin, Mendi A Higgins, F Christopher Zusi, et al.
Journal of Medicinal Chemistry|June 17, 2016
Discovery and Structure-Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1)John L Gilmore, James E Sheppeck, Scott H Watterson, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Journal of Molecular Biology|January 13, 2015
Developing Adnectins that target SRC co-activator binding to PXR: a structural approach toward understanding promiscuity of PXRJaved A Khan, Daniel M Camac, Simon Low, et al.
Journal of Medicinal Chemistry|April 4, 2007
Dihydropyridopyrazinones and dihydropteridinones as corticotropin-releasing factor-1 receptor antagonists: structure-activity relationships and computational modelingCarolyn D Dzierba, Andrew J Tebben, Richard G Wilde, et al.
ACS Medicinal Chemistry Letters|April 21, 2015
Discovery of a Potent and Orally Bioavailable Dual Antagonist of CC Chemokine Receptors 2 and 5Percy H Carter, Gregory D Brown, Robert J Cherney, et al.
Bioorganic & Medicinal Chemistry Letters|December 22, 2007
From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxisJoseph B Santella, Daniel S Gardner, Wenqing Yao, et al.
ACS Medicinal Chemistry Letters|January 29, 2016
Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate CancerAudris Huang, Lata Jayaraman, Aberra Fura, et al.
Journal of Medicinal Chemistry|October 4, 2012
Acyl guanidine inhibitors of β-secretase (BACE-1): optimization of a micromolar hit to a nanomolar lead via iterative solid- and solution-phase library synthesisSamuel W Gerritz, Weixu Zhai, Shuhao Shi, et al.
Bioorganic & Medicinal Chemistry Letters|May 28, 2013
The discovery of BMS-457, a potent and selective CCR1 antagonistDaniel S Gardner, Joseph B Santella, John V Duncia, et al.
ACS Medicinal Chemistry Letters|June 18, 2021
Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2Michael G Yang, Zili Xiao, Rulin Zhao, et al.
Bioorganic & Medicinal Chemistry Letters|November 17, 2010
Synthesis and SAR of indole-and 7-azaindole-1,3-dicarboxamide hydroxyethylamine inhibitors of BACE-1Lawrence R Marcin, Mendi A Higgins, F Christopher Zusi, et al.
Journal of Medicinal Chemistry|June 17, 2016
Discovery and Structure-Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1)John L Gilmore, James E Sheppeck, Scott H Watterson, et al.
Pageof 5